ANEBULO PHARMACEUTICALS INC (ANEB)
US0345691036 - Common Stock
ANEBULO PHARMACEUTICALS INC
NASDAQ:ANEB (9/27/2023, 7:11:39 PM)
After market: 3.48 +0.42 (+13.73%)3.06
-0.01 (-0.33%)
Company Profile
Anebulo Pharmaceuticals, Inc. engages in the provision of pharmaceutical services. The company is headquartered in Lakeway, Texas and currently employs 4 full-time employees. The company went IPO on 2021-05-07. The firm is engaged in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The Company’s lead product candidate is ANEB-001, a potent, small molecule cannabinoid receptor antagonist, to address the unmet medical need for a specific antidote for ACI. ANEB-001, is intended to rapidly reverse the negative effects of ACI within one hour of administration. The signs and symptoms of ACI range from profound sedation to anxiety and panic to psychosis with hallucinations. CB1 receptors are concentrated in the brain and central nervous system, while CB2 receptors are found mostly in peripheral organs and are associated with the immune system.
Company Info
ANEBULO PHARMACEUTICALS INC
Jfl Capital Management, 1017 Rr 620 S, Suite 107
Lakeway TEXAS
P: 17372035270.0
CEO: Daniel Schneeberger
Employees: 4
Website: https://www.anebulo.com/
ANEB News
7 days ago - Anebulo Pharmaceuticals, Inc.Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates
a month ago - Anebulo Pharmaceuticals, Inc.Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences
a month ago - Anebulo Pharmaceuticals, Inc.Anebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 Extension
5 months ago - Anebulo Pharmaceuticals, Inc.Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent Updates/PRNewswire/ -- Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from...
6 months ago - Anebulo Pharmaceuticals, Inc.Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid Intoxication/PRNewswire/ -- Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (the "Company" or "Anebulo"), a clinical-stage biopharmaceutical company developing novel...
8 months ago - Anebulo Pharmaceuticals, Inc.Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent UpdatesANEB Twits
Here you can normally see the latest stock twits on ANEB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
